Biotech Series C Investors & VC Firms

600 firms in this list, with a median first check of $1M. 112 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
SA Safar Partners GSBMRMAC20 people	88🔒	Cambridge	US	Pre-Seed–Late Stage	—	+ Add to CRM
PM PMV TB1 person · Leads rounds	88🔒	Brussels	BE	Pre-Seed–Late Stage	—	+ Add to CRM
UT UTEC KM1 person · Follows rounds	88🔒	Tokyo	JP	Pre-Seed–Growth	$3.1M – $78M	+ Add to CRM
AM aMoon IDMMRSRW25 people	88🔒	Ra'anana	IL	Seed–Late Stage	—	+ Add to CRM
IM Impact Fund Denmark ADABAWAF36 people	88🔒	Copenhagen	DK	Seed–Late Stage	$2.2M – $70.2M	+ Add to CRM
MC McWin Capital Partners HMSKGCHG31 people	88🔒	London	GB	Series B–Late Stage	—	+ Add to CRM
RH Rho Ventures HKJRMLDR10 people	88🔒	New York	US	Pre-Seed–Late Stage	$2M – $15M	+ Add to CRM
CL Claret Capital Partners DBJKBGDM29 people	88🔒	London	GB	Series A–Late Stage	—	+ Add to CRM
NO Novartis Venture Fund AKBDFMLB25 people · Leads rounds	88🔒	Basel	CH	Pre-Seed–Late Stage	$5M – $25M	+ Add to CRM
CE CEI Ventures CJNHSBBB18 people	88🔒	Brunswick	US	Seed–Late Stage	$1M – $4M	+ Add to CRM
EC EcoR1 Capital ONCSSMBZ17 people	88🔒	San Francisco	US	Seed–Late Stage	—	+ Add to CRM
MO Movac PMDBFFJG26 people · Leads rounds	88🔒	Auckland	NZ	Seed–Late Stage	$600K – $3M	+ Add to CRM
BI BioMedPartners ANSFDCDD28 people · Leads rounds	88🔒	Basel	CH	Seed–Late Stage	$648K – $6.5M	+ Add to CRM
LD LDC CHDADADB12 people	88🔒	London	GB	Series B–Growth	$12.7M – $127M	+ Add to CRM
PA Parkwalk Advisors MWJPAWAD31 people · Follows rounds	88🔒	London	GB	Seed–Growth	—	+ Add to CRM
UK UKSE SHMSAPAC34 people	88🔒	Sheffield	GB	Series A–Late Stage	$31.8K – $1.3M	+ Add to CRM
MP MPM Capital AGBMDBES27 people	88🔒	—	US	Pre-Seed–Late Stage	—	+ Add to CRM
AC ACT Venture Capital JFDRCMCM10 people	88🔒	Dublin	IE	Seed–Growth	$1.1M – $16.2M	+ Add to CRM
WI WI Harper Group PLCWELKS25 people	88🔒	San Francisco	US	Seed–Series C	$5M – $15M	+ Add to CRM
PA Pan-Lin Capital 李刘薛谭5 people · Leads rounds	88🔒	Shanghai	CN	Pre-Seed–Growth	—	+ Add to CRM
SP SPRINGROCK VENTURES EBKMCBDS14 people	88🔒	Seattle	US	Seed–Late Stage	$2M – $5M	+ Add to CRM
LU Lumira Ventures BRPVDHGB17 people	88🔒	Toronto	CA	Pre-Seed–Late Stage	$1M – $10M	+ Add to CRM
PE Peregrine Ventures ELBLELLS14 people	88🔒	Or Yehuda	IL	Seed–Late Stage	$500K – $3M	+ Add to CRM
VI Visionaries Club JBMSRJSM16 people · Follows rounds	88🔒	Berlin	DE	Pre-Seed–Late Stage	$900K	+ Add to CRM

Safar Partners

CambridgePre-Seed–Late Stage

GSBMRMAC20 people

PMV

BrusselsPre-Seed–Late Stage

TB1 person

UTEC

TokyoPre-Seed–Growth$3.1M – $78M

KM1 person

aMoon

Ra'ananaSeed–Late Stage

IDMMRSRW25 people

Impact Fund Denmark

CopenhagenSeed–Late Stage$2.2M – $70.2M

ADABAWAF36 people

McWin Capital Partners

LondonSeries B–Late Stage

HMSKGCHG31 people

Rho Ventures

New YorkPre-Seed–Late Stage$2M – $15M

HKJRMLDR10 people

Claret Capital Partners

LondonSeries A–Late Stage

DBJKBGDM29 people

Novartis Venture Fund

BaselPre-Seed–Late Stage$5M – $25M

AKBDFMLB25 people

CEI Ventures

BrunswickSeed–Late Stage$1M – $4M

CJNHSBBB18 people

EcoR1 Capital

San FranciscoSeed–Late Stage

ONCSSMBZ17 people

Movac

AucklandSeed–Late Stage$600K – $3M

PMDBFFJG26 people

BioMedPartners

BaselSeed–Late Stage$648K – $6.5M

ANSFDCDD28 people

LDC

LondonSeries B–Growth$12.7M – $127M

CHDADADB12 people

Parkwalk Advisors

LondonSeed–Growth

MWJPAWAD31 people

UKSE

SheffieldSeries A–Late Stage$31.8K – $1.3M

SHMSAPAC34 people

MPM Capital

Pre-Seed–Late Stage

AGBMDBES27 people

ACT Venture Capital

DublinSeed–Growth$1.1M – $16.2M

JFDRCMCM10 people

WI Harper Group

San FranciscoSeed–Series C$5M – $15M

PLCWELKS25 people

Pan-Lin Capital

ShanghaiPre-Seed–Growth

李刘薛谭5 people

SPRINGROCK VENTURES

SeattleSeed–Late Stage$2M – $5M

EBKMCBDS14 people

Lumira Ventures

TorontoPre-Seed–Late Stage$1M – $10M

BRPVDHGB17 people

Peregrine Ventures

Or YehudaSeed–Late Stage$500K – $3M

ELBLELLS14 people

Visionaries Club

BerlinPre-Seed–Late Stage$900K

JBMSRJSM16 people

Data sourced from public filings and firms' own websites — see our methodology.